Parallel Symposia

Symposium 1: Towards Understanding of Tissue Transporter Interactions: Impact on Drug Efficacy/Safety and Tissue Targeting
Chair: Aleksandra Galetin, University of Manchester

  • Tissue Transporter Drug-Drug Interactions: Safety/Efficacy Concerns Not Readily Apparent from Systemic Exposure
    Aleksandra Galetin, University of Manchester
  • Integration of Imaging Techniques to Study Tissue Distribution of Drugs
    Hiroyuki Kusuhara, University of Tokyo
  • Drug Efficacy Associated with Renal Apical Transporter
    Caroline Lee, Ardea Biosciences
  • Renal Transporters:  Mediators of Drug Disposition and Action
    Kathy Giacomini, University of California, San Francisco

Symposium 2: Drug Discovery and Development in the Trenches
Chairs: Cornelis (Marcel) Hop, Genentech and Natalie Hosea, Takeda

  • Venetoclax: DMPK Challenges and Opportunities from Discovery to Market
    Daniel Bow, Abbvie
  • Challenges in Human Projections for Prodrugs: GS-6620 for HCV
    Adrian Ray, Gilead
  • Development of Daclatasvir: Opportunities and Challenges Along the Way
    Griff Humphreys, Bristol-Myers Squibb
  • ADME Challenges Encountered During the Development of Osimertinib; an Irreversible EGFR Inhibitor
    Martin Wild, AstraZeneca

Symposium 3: Biomarkers of Safety and DDI (Transport and Metabolism) 
Chairs: Yurong Lai, Gilead Science and Jose Manautou, University of Connecticut

  • Novel Genetic Determinants of Acetaminophen Toxicity with the Potential for Validation of Biomarkers
    Jose Manautou, University of Connecticut
  • Endogenous Probes for Transporter Mediated Drug-Drug Interaction
    Yurong Lai, Gilead Science
  • Novel Biomarkers in DILI: the Development of Novel DILI Biomarkers and Therapeutic Interventions
    Daniel Antoine, University of Liverpool
  • Applications and Challenges of Using Endogenous Biomarkers for CYP DDI Evaluation
    Yvonne Lin,  University of Washington

Symposium 4: When is a PBPK Model Fit for Purpose? Insights to Model Acceptance Criteria, Extrapolation to Different Populations, and Modeling Population Variability
Chairs: Ping Zhao and Nina Isoherranen, University of Washington

  • Industry Perspective of FDA PBPK Guidance and EMA PBPK Guideline: Report from IQC
    Hannah Jones, Pfizer
  • Assessment of the Predictive Performance of PBPK Models
    Ping Zhao
  • How Should a PBPK Model be Evaluated for Intended Use?
    Nina Isoherranen, University of Washington

Symposium 5: ADME/PK Considerations for Next Generation Therapeutics: ADCs, Antibodies, Oligonucleotides, and Liposomes
Chairs: Anshul Gupta, Amgen and Steve Alley, Seattle Genetics

  • Targeted Drug Delivery and ADME of Antibody-Drug Conjugates
    Steve Alley, Seattle Genetics
  • Imaging and Kinetics of Nanoparticle Disposition in Patient Tumors
    Mauricio  Leal, Pfizer
  • Pharmacokinetics and Pharmacodynamics of Oligonucleotide Therapeutics:  Different, but Strangely Familiar
    Art Levin
  • In vitro & in vivo ADME Considerations for Guiding Engineering of Next Generation of Protein Therapeutics
    Josh Pearson, Amgen

Symposium 6: Transporters and Enzymes: Novel Insights into the Regulation of Drug Disposition and Response
Chairs: Young Jeong, University of Illinois, Chicago and Guofeng You, Rutgers University

  • Role of lncRNAs in the Regulation of Drug Metabolizing Enzymes
    Xiabao Zhong, University of Connecticut
  • Understanding the Gut Microbiome-Liver Axis in Xenobiotic Biotransformation
    Julia Yue Cui, University of Washington
  • Genetic Regulation of Efflux Drug Transporters
    Lauren Aleksunes, Rutgers University
  • Post-Translational Regulation of Influx Drug Transporters
    Guofeng You, Rutgers University

Symposium 7: Molybdenum Coenzymes (e.g. AO and XO) – Basics and Application
Chair: R. Scott Obach, Pfizer

  • Biochemical Aspects of Aldehyde and Xanthine Oxidase
    Jeff Jones, Washington State University
  • Crystal Structure of Aldehyde Oxidase
    Maria Joao Romao, Universidade Nova de Lisboa
  • Genetics, Regulation, and Endogenous Role for Aldehyde Oxidase
    Enrico Garattini, Mario Negri Research Institute
  • Aldehyde Oxidase in Drug Design and Drug Discovery
    R. Scott Obach, Pfizer

Symposium 8: Interplay of Transporters and Mitochondrial/Lysosomal Drug Sequestration–Implications in Toxicity, Efficacy and Drug-Drug Interactions
Chairs: Wei Yue, University of Oklahoma Health Sciences Center and Yingying Guo, Eli Lilly and Company

  • Utility of Humanized Liver Mouse Model in Evaluation of Mitochondrial Transporters-Associated Hepatotoxicity
    Yingying Guo, Eli Lilly and Company
  • Targeting the Lysosome with Novel Drugs to Overcome P-glycoprotein Mediated Resistance in Cancer
    Des R. Richardson, University of Sydney
  • The Contribution of Lysosomal Sequestration to Intracellular Drug Accumulation and its Assessment by in vitro and in silico Methods
    Ayse Ufuk, University of Manchester
  • Impaired OATP1B1-mediated Transport Following Treatment with Lysosomotropic Drug Chloroquine: Implications in OATP-mediated Drug-Drug Interactions
    Wei Yue, The University of Oklahoma Health Sciences Center

Symposium 9: Mitochondrial Metabolism, Transport, and Toxicity
Chairs: Allan Rettie, University of Washington and Yvonne Will, Pfizer

  • Introduction to Basic Mitochondrial Biology as it Relates to Drug Induced Toxicity
    James Dykens, EyeCyte Therapeutics
  • Mitochondrial Transporters and How They Affect Drug Accumulation/Toxicity
    Ferdinando Palmieri, University of Bari
  • P450 Metabolism and Effects on Drug Accumulation/Toxicity: Examples of Compounds Causing Liver Injury
    Narayan Avadhani, University of Pennsylvania
  • Mitochondrial Toxicity: In vitro Testing Paradigm and Potential Biomarker Development
    Yvonne Will, Pfizer

Symposium 10: Hydrolases: Enzymology and Role in Drug Development
Chairs: Griff Humphreys, Bristol-Myers Squibb and Andrew Parkinson, XPD Consulting

  • Evaluating in vivo Esterase-mediated Drug Metabolism: Should Be Easy, But Why Do We Fail?
    Phil Potter, St. Jude Children's Research Hospital
  • Chemical Biology Approaches to Profile Esterase Function
    Brent Martin, University of Michigan
  • Genetic Polymorphisms of Carboxylesterases and their Clinical Implications
    Haojie Zhu, University of Michigan
  • Functional Significance of Orphan Drug-metabolizing Esterases in Pharmacokinetics and Toxicities
    Tatsuki Fukami, Kanazawa University

Symposium 11: New Insights into P450 Structure, Emerging Transporters, and Application to Drug Development  
Chairs: Eric Johnson, The Scripps Research Institute and Joanne Wang, University of Washington

  • Structural Differences Exhibited by Cytochrome P450s 3A5 and 3A4
    Eric Johnson, The Scripps Research Institute
  • Utilizing Structures of 2D6 and BACE1 to Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors
    Michael A. Brodney, Pfizer
  • Renal MATE Function in the Context of Drug Development
    Stephen Wright, University of Arizona
  • Novel Organic Cation Transporter PMAT: Structure, Function, and Role in Drug Transport at the Blood-CSF Barrier
    Joanne Wang, University of Washington

Symposium 12: Emergent Technologies for Evaluating Drug and Xenobiotic Disposition
Chairs: Ed Kelly, University of Washington and Jinping Gan, Bristol-Myers Squibb

  • Utility of Microphysiological System (MPS) Technologies in Drug and Xenobiotic Safety Assessments
    Ed Kelly, University of Washington
  • What Can Single-Molecule Fluorescence Tell Us About the Disposition of Large- and Small-Molecule Drugs?
    Abhi Nath, University of Washington
  • The Utility of 3D Hepatocyte Spheroids in Addressing Modern Problems in Drug Metabolism
    Jinping Gan, Bristol-Myers Squibb
  • Visualizing Drug Disposition with MALDI Imaging MS
    Steve Castellino, GlaxoSmithKline